Lexeo Therapeutics (LXEO) Common Equity: 2022-2023
- Lexeo Therapeutics' Common Equity fell 64.49% to -$162.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$162.8 million, marking a year-over-year decrease of 64.49%. This contributed to the annual value of -$113.0 million for FY2022, which is N/A change from last year.
- According to the latest figures from Q3 2023, Lexeo Therapeutics' Common Equity is -$162.8 million, which was down 44.14% from -$113.0 million recorded in Q4 2022.
- Over the past 5 years, Lexeo Therapeutics' Common Equity peaked at -$99.0 million during Q3 2022, and registered a low of -$162.8 million during Q3 2023.
- In the last 2 years, Lexeo Therapeutics' Common Equity had a median value of -$113.0 million in 2022 and averaged -$124.9 million.
- Data for Lexeo Therapeutics' Common Equity shows a maximum YoY tumbled of 64.49% (in 2023) over the last 5 years.
- Over the past 2 years, Lexeo Therapeutics' Common Equity (Quarterly) stood at -$113.0 million in 2022, then slumped by 64.49% to -$162.8 million in 2023.
- Its Common Equity was -$162.8 million in Q3 2023, compared to -$113.0 million in Q4 2022 and -$99.0 million in Q3 2022.
